ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update [Yahoo! Finance]
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation [Yahoo! Finance]
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults [Yahoo! Finance]